Cat. No.
MABL-760
Application
IP, Therapeutic (block), FC, IHC
Isotype
Engineer antibody
Species Reactivity
Human
Clone No.
BU12
From
Recombinant Antibody
Specificity
BU12 reacts specifically with CD19.
Alternative Names
Leu12; CD19 Molecule; B-Lymphocyte Surface Antigen B4; T-Cell Surface Antigen Leu-12; Differentiation Antigen CD19; CD19 Antigen; CVID3; B4
UniProt
P15391
Immunogen
The anti-CD19 antibody-producing hybridoma clone BU-12 was produced by the immunisation of two BALB/c mice with the Burkitt's lymphoma cell line EB4. Immune spleen cells from these animals were fused with the mouse X63 AG8 653 plasmacytoma cell line and resulting hybridomas selected in HAT medium. Screening of hybridoma culture supernatants on a range of T-, B-, myeloid and erythroid cell lines and on sections of normal human tonsil led to the selection of the pan-B-cell-reactive BU- 12 hybridoma clone.
Application Notes
BU12 has been found to inhibit specific antibody responses by tonsillar mononuclear cells to influenza virus, and IgG secretion by B lymphoblastoid cell line stimulated with IL-6 (Callard 1992). BU12 has also been used in FACS and radio-iodinated antibody binding studies to determine the levels of CD19 expression on the surface of Ramos and NALM-6 cells (Flavell 2006).
Antibody First Published
DJ Flavell et al. Preclinical studies with the anti-CD19-saporin immunotoxin BU12-SAPORIN for the treatment of human-B-cell tumours Briftsh Joumal of Cancer (1995) 72, 1373-1379 PMID:8519647
Note on publication
Describes the construction of immunotoxin BU12-SAPORIN, and its use for selective cytotoxicity of CD19+ target cells in vitro and in vivo.
Size
100 μg Purified antibody.
Concentration
1 mg/ml.
Purification
Protein A affinity purified
Buffer
PBS with 0.02% Proclin 300.
Storage Recommendation
Store at 4⁰C for up to 3 months. For longer storage, aliquot and store at - 20⁰C.
